Junji Tsurutani, Hiroji Iwata, Ian Krop, Pasi A Jänne, Toshihiko Doi, Shunji Takahashi, Haeseong Park, Charles Redfern, Kenji Tamura, Trisha M Wise-Draper, Kaku Saito, Masahiro Sugihara, Jasmeet Singh, Takahiro Jikoh, Gilles Gallant, Bob T Li. Cancer Discov 2020
Times Cited: 98
Times Cited: 98
J Mazieres, A Drilon, A Lusque, L Mhanna, A B Cortot, L Mezquita, A A Thai, C Mascaux, S Couraud, R Veillon, M Van den Heuvel, J Neal, N Peled, M Früh, T L Ng, V Gounant, S Popat, J Diebold, J Sabari, V W Zhu, S I Rothschild, P Bironzo, A Martinez-Marti, A Curioni-Fontecedro, R Rosell, M Lattuca-Truc, M Wiesweg, B Besse, B Solomon, F Barlesi, R D Schouten, H Wakelee, D R Camidge, G Zalcman, S Novello, S I Ou, J Milia, O Gautschi. Ann Oncol 2019
Times Cited: 373
Times Cited: 373
List of shared articles
Times cited
Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian R Chirieac, Thomas A D'Amico,[...]. J Natl Compr Canc Netw 2022
David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian R Chirieac, Thomas A D'Amico,[...]. J Natl Compr Canc Netw 2022
Clinicopathologic features and treatment advances in cancers with HER2 alterations.
Shuyi Cen, Zhen Liu, Hongming Pan, Weidong Han. Biochim Biophys Acta Rev Cancer 2021
Shuyi Cen, Zhen Liu, Hongming Pan, Weidong Han. Biochim Biophys Acta Rev Cancer 2021
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.
Aaron C Tan, Daniel S W Tan. J Clin Oncol 2022
Aaron C Tan, Daniel S W Tan. J Clin Oncol 2022
HER2 Aberrations in Non-Small Cell Lung Cancer: From Pathophysiology to Targeted Therapy.
Ioannis A Vathiotis, Andriani Charpidou, Niki Gavrielatou, Konstantinos N Syrigos. Pharmaceuticals (Basel) 2021
Ioannis A Vathiotis, Andriani Charpidou, Niki Gavrielatou, Konstantinos N Syrigos. Pharmaceuticals (Basel) 2021
Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies.
Mihaela Aldea, Fabrice Andre, Aurelien Marabelle, Semih Dogan, Fabrice Barlesi, Jean-Charles Soria. Cancer Discov 2021
Mihaela Aldea, Fabrice Andre, Aurelien Marabelle, Semih Dogan, Fabrice Barlesi, Jean-Charles Soria. Cancer Discov 2021
Progress in Treatment of Non-Small Cell Lung Cancer Harboring HER2 Aberrations.
Jun Ni, Li Zhang. Onco Targets Ther 2021
Jun Ni, Li Zhang. Onco Targets Ther 2021
Consensus for HER2 alterations testing in non-small-cell lung cancer.
S Ren, J Wang, J Ying, T Mitsudomi, D H Lee, Z Wang, Q Chu, P C Mack, Y Cheng, J Duan,[...]. ESMO Open 2022
S Ren, J Wang, J Ying, T Mitsudomi, D H Lee, Z Wang, Q Chu, P C Mack, Y Cheng, J Duan,[...]. ESMO Open 2022
Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study.
Xiangling Chu, Huiping Qiang, Mengqing Xie, Xing Li, Jing Zhao, Yan Wu, Juan Zhou, Jinyan Ye, Chao Zhao, Chaonan Han,[...]. Cancer Immunol Immunother 2022
Xiangling Chu, Huiping Qiang, Mengqing Xie, Xing Li, Jing Zhao, Yan Wu, Juan Zhou, Jinyan Ye, Chao Zhao, Chaonan Han,[...]. Cancer Immunol Immunother 2022
Overcoming therapy resistance in EGFR-mutant lung cancer.
Antonio Passaro, Pasi A Jänne, Tony Mok, Solange Peters. Nat Cancer 2021
Antonio Passaro, Pasi A Jänne, Tony Mok, Solange Peters. Nat Cancer 2021
Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring.
Damien Reita, Lucile Pabst, Erwan Pencreach, Eric Guérin, Laurent Dano, Valérie Rimelen, Anne-Claire Voegeli, Laurent Vallat, Céline Mascaux, Michèle Beau-Faller. Cancers (Basel) 2021
Damien Reita, Lucile Pabst, Erwan Pencreach, Eric Guérin, Laurent Dano, Valérie Rimelen, Anne-Claire Voegeli, Laurent Vallat, Céline Mascaux, Michèle Beau-Faller. Cancers (Basel) 2021
HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies.
Xin Yu, Xianxiu Ji, Chunxia Su. Front Oncol 2022
Xin Yu, Xianxiu Ji, Chunxia Su. Front Oncol 2022
Efficacy of Combination Chemo-Immunotherapy as a First-Line Treatment for Advanced Non-Small-Cell Lung Cancer Patients With HER2 Alterations: A Case Series.
Shuang Zhao, Xinghong Xian, Panwen Tian, Weimin Li, Ke Wang, Yalun Li. Front Oncol 2021
Shuang Zhao, Xinghong Xian, Panwen Tian, Weimin Li, Ke Wang, Yalun Li. Front Oncol 2021
Lung cancer.
Alesha A Thai, Benjamin J Solomon, Lecia V Sequist, Justin F Gainor, Rebecca S Heist. Lancet 2021
Alesha A Thai, Benjamin J Solomon, Lecia V Sequist, Justin F Gainor, Rebecca S Heist. Lancet 2021
Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations.
M Riudavets, I Sullivan, P Abdayem, D Planchard. ESMO Open 2021
M Riudavets, I Sullivan, P Abdayem, D Planchard. ESMO Open 2021
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.
David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian R Chirieac, Thomas A D'Amico,[...]. J Natl Compr Canc Netw 2021
David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian R Chirieac, Thomas A D'Amico,[...]. J Natl Compr Canc Netw 2021
Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.
Bob T Li, Egbert F Smit, Yasushi Goto, Kazuhiko Nakagawa, Hibiki Udagawa, Julien Mazières, Misako Nagasaka, Lyudmila Bazhenova, Andreas N Saltos, Enriqueta Felip,[...]. N Engl J Med 2022
Bob T Li, Egbert F Smit, Yasushi Goto, Kazuhiko Nakagawa, Hibiki Udagawa, Julien Mazières, Misako Nagasaka, Lyudmila Bazhenova, Andreas N Saltos, Enriqueta Felip,[...]. N Engl J Med 2022
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma.
Giuseppe Lamberti, Elisa Andrini, Monia Sisi, Alessandro Rizzo, Claudia Parisi, Alessandro Di Federico, Francesco Gelsomino, Andrea Ardizzoni. Crit Rev Oncol Hematol 2020
Giuseppe Lamberti, Elisa Andrini, Monia Sisi, Alessandro Rizzo, Claudia Parisi, Alessandro Di Federico, Francesco Gelsomino, Andrea Ardizzoni. Crit Rev Oncol Hematol 2020